Impact of inotuzumab ozogamicin as bridging therapy and tumor burden in CAR-T therapy for B-acute lymphoblastic leukemia
IntroductionInotuzumab ozogamicin is increasingly being used as bridging therapy (BT) prior to chimeric antigen receptor T-cell (CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (R/R ALL), but its impact on CAR-T expansion and clinical…